Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
| Revenue (Most Recent Fiscal Year) | $183.88M |
| Net Income (Most Recent Fiscal Year) | $-83.50M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -33.05% |
| Net Margin (Trailing 12 Months) | -34.17% |
| Return on Equity (Trailing 12 Months) | -24.48% |
| Return on Assets (Trailing 12 Months) | -10.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.91 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.55 |
| Inventory Turnover (Trailing 12 Months) | 0.11 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 642.47M |
| Free Float | 631.49M |
| Market Capitalization | $1.02B |
| Average Volume (Last 20 Days) | 9.55M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.71% |
| Percentage Held By Institutions (Latest 13F Reports) | 73.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |